Previous 10 | Next 10 |
On track to complete enrollment of Phase 2 lung cancer trial in Q2 2019 and report additional interim data in Q4 2019 Anticipates receiving additional $6.9 million in grant funds after filing PTX-35 IND DURHAM, NC / ACCESSWIRE / May 15, 2019 / Heat Biologics, Inc. (NASDAQ: HT...
DURHAM, NC / ACCESSWIRE / May 6, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, is scheduled to prese...
DURHAM, NC / ACCESSWIRE / April 18, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, announces that Jeff Wolf, Chief Executive Officer, is scheduled to present at the ThinkEquit...
Animal Study Demonstrates Combination of HS-110 and HS-130 Yields Three-Fold Increase in Anti-Tumor CD8+ T-cell Expansion DURHAM, NC / ACCESSWIRE / April 2, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patien...
Heat Biologics (NASDAQ: HTBX ): FY GAAP EPS of -$0.90 beats by $0.18 . More news on: Heat Biologics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Recently announced interim HS-110 Phase 2 data demonstrating survival benefit in patients with ‘cold' tumors (CD8+ TILs < 10% at baseline) who are least likely to respond to checkpoint inhibitors alone Preliminary data suggests the addition of HS-110 to Bristol-Myers Squibb's ...
DURHAM, NC / ACCESSWIRE / March 21, 2019 / Heat Biologics,Inc. (NASDAQ: HTBX), a biopharmaceutical company developing immunotherapies designed to activate a patient's immune system against cancer, today announced an oral presentation to be held at the Chinese Society for Clinical Oncology ...
DURHAM, NC / ACCESSWIRE / March 5, 2019 / Heat Biologics, Inc. (NASDAQ: HTBX), a biopharmaceutical company developing "off-the-shelf" T-cell therapies designed to activate a patient's immune system against cancer, today announced that John Prendergast, Heat Biologic's Lead Board member, wi...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +130% . Puma Biotechnology (NYSE: PBYI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +30% . GlobalSCAPE (NYSEMKT: GSB ) +29% . Castlight Health (NYSE: CSLT ) +24% . Farfetch Limited (NYSE: FTCH ) +23% . Sequential Brands Group (NASD...
ImmunoGen (NASDAQ: IMGN ) -46% after mirvetuximab soravtansine flunks late-stage study. More news on: ImmunoGen, Inc., Mersana Therapeutics, Nutanix, Stocks on the move, Read more ...
News, Short Squeeze, Breakout and More Instantly...
DURHAM, N.C., July 18, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) , (“Scorpius” or the “Company”), an integrated contract development and manufacturing organization (CDMO), today announced the successful execution of its first...
DURHAM, N.C., July 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today announced that the Company’s Board of ...
DURHAM, N.C., June 17, 2024 (GLOBE NEWSWIRE) -- Scorpius Holdings, Inc (NYSE American: SCPX) (“Scorpius” or “the Company”), an integrated contract development and manufacturing organization (“CDMO”), today reported that it received notice ...